Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effect of the Addition of Dronedarone to, Versus Increase of, Existing Conventional Rate Control Medication on Ventricular Rate During Paroxysmal or Persistent Atrial Fibrillation.

Next Previous
Trial Profile

The Effect of the Addition of Dronedarone to, Versus Increase of, Existing Conventional Rate Control Medication on Ventricular Rate During Paroxysmal or Persistent Atrial Fibrillation.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Nov 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dronedarone (Primary) ; Beta adrenergic receptor antagonists; Calcium channel antagonists; Digoxin
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms AFRODITE
  • Sponsors Sanofi

Most Recent Events

  • 09 Nov 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
  • 09 Nov 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
  • 09 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top